Standard Financial Statements From 2010 to 2026

LAB Stock  USD 1.63  0.12  7.95%   
Standard Biotools' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Standard Biotools' valuation are provided below:
Gross Profit
81.9 M
Profit Margin
(0.76)
Market Capitalization
592.2 M
Enterprise Value Revenue
2.5022
Revenue
169.7 M
We have found one hundred twenty available fundamental trend indicators for Standard Biotools, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Standard Biotools current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 478.1 M, whereas Enterprise Value is forecasted to decline to about 274.1 M.

Standard Biotools Total Revenue

210.63 Million

Check Standard Biotools financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Standard Biotools' main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.9 M, Interest Expense of 4.4 M or Total Revenue of 210.6 M, as well as many indicators such as Price To Sales Ratio of 4.32, Dividend Yield of 0.0 or PTB Ratio of 1.93. Standard financial statements analysis is a perfect complement when working with Standard Biotools Valuation or Volatility modules.
  
Build AI portfolio with Standard Stock
Check out the analysis of Standard Biotools Correlation against competitors.
For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.

Standard Biotools Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets739.4 M704.2 M332.7 M
Slightly volatile
Short and Long Term Debt Total36 M37.9 M115 M
Slightly volatile
Other Current Liabilities32.9 M31.3 M16.8 M
Slightly volatile
Total Current Liabilities79.6 M75.8 M42.8 M
Slightly volatile
Property Plant And Equipment Net86.2 M82.1 M33.7 M
Slightly volatile
Current Deferred Revenue22.4 M21.4 M11.3 M
Slightly volatile
Accounts Payable14.8 M14.1 MM
Slightly volatile
Cash201.3 M191.7 M70.3 M
Slightly volatile
Non Current Assets Total285.5 M271.9 M165.7 M
Slightly volatile
Non Currrent Assets Other30 M28.6 M8.6 M
Slightly volatile
Cash And Short Term Investments353.6 M336.8 M123 M
Slightly volatile
Net Receivables40.6 M38.6 M20.1 M
Slightly volatile
Common Stock Shares Outstanding425.8 M405.6 M104.8 M
Slightly volatile
Liabilities And Stockholders Equity739.4 M704.2 M332.7 M
Slightly volatile
Non Current Liabilities Total81.6 M85.9 M153.5 M
Pretty Stable
Inventory49.2 M46.8 M20 M
Slightly volatile
Other Current Assets10.5 M10 M4.5 M
Slightly volatile
Other Stockholder EquityB1.9 B780.1 M
Slightly volatile
Total Liabilities220.5 M161.7 M199.7 M
Slightly volatile
Total Current Assets453.9 M432.3 M167.1 M
Slightly volatile
Common Stock478.2 K455.4 K115.8 K
Slightly volatile
Intangible Assets37.5 M26.1 M37 M
Very volatile
Good Will116.1 M128 M107.2 M
Slightly volatile
Other Assets3.4 M2.8 M5.7 M
Slightly volatile
Long Term Debt255.6 K269.1 K116 M
Slightly volatile
Long Term Debt Total91.1 M56.5 M131.8 M
Slightly volatile
Capital Surpluse774.5 M974.1 M666.6 M
Slightly volatile
Cash And Equivalents98.2 M93.5 M44.3 M
Slightly volatile
Property Plant Equipment36.3 M68.5 M32.6 M
Slightly volatile
Other Liabilities28.7 M23.2 M23.4 M
Pretty Stable
Non Current Liabilities Other8.4 MM2.6 M
Slightly volatile
Net Working Capital374.3 M356.5 M130 M
Slightly volatile
Capital Lease Obligations35.4 M37.6 M18.9 M
Slightly volatile
Property Plant And Equipment Gross174.6 M166.3 M52.1 M
Slightly volatile
Short and Long Term Debt71.9 M68.5 M20.2 M
Slightly volatile
Warrants249 M280.1 M305.8 M
Slightly volatile
Common Stock Total Equity64 K72 K78.6 K
Slightly volatile

Standard Biotools Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization10.9 M19.4 M12.5 M
Slightly volatile
Interest Expense4.4 M3.8 M4.4 M
Pretty Stable
Total Revenue210.6 M200.6 M111.7 M
Slightly volatile
Gross Profit50.9 M96.9 M57.6 M
Slightly volatile
Other Operating Expenses422.2 M402.1 M188.1 M
Slightly volatile
Research Development75.4 M71.8 M36.9 M
Slightly volatile
Cost Of Revenue108.9 M103.7 M51.1 M
Slightly volatile
Total Operating Expenses313.3 M298.4 M137 M
Slightly volatile
Interest Income15.6 M23.2 M11.8 M
Slightly volatile
Selling General Administrative110.5 M180.1 M103.2 M
Slightly volatile
Reconciled Depreciation12.6 M15.2 M15.9 M
Slightly volatile
Non Operating Income Net OtherM1.1 M1.2 M
Slightly volatile

Standard Biotools Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation38.3 M36.5 M15.4 M
Slightly volatile
Begin Period Cash Flow42.4 M60.4 M43.8 M
Slightly volatile
Depreciation10.7 M19.4 M12.2 M
Slightly volatile
Capital Expenditures4.9 M9.6 M5.6 M
Slightly volatile
End Period Cash Flow203.8 M194.1 M71.1 M
Slightly volatile
Change To Netincome22.8 M35.3 M19 M
Slightly volatile
Dividends Paid255.6 K269.1 KM
Slightly volatile
Change Receivables850.4 K956.7 KM
Slightly volatile
Cash And Cash Equivalents Changes42.6 M47.9 M52.3 M
Slightly volatile
Cash Flows Other Operating56.3 M63.3 M69.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.324.074.0572
Slightly volatile
Days Sales Outstanding82.9880.8769.2341
Pretty Stable
Stock Based Compensation To Revenue0.0880.160.1137
Slightly volatile
Capex To Depreciation0.870.570.8262
Slightly volatile
EV To Sales4.513.194.3629
Slightly volatile
Inventory Turnover1.992.21352.5788
Pretty Stable
Days Of Inventory On Hand196190158
Slightly volatile
Payables Turnover5.26.617.1898
Pretty Stable
Research And Ddevelopement To Revenue0.620.410.4615
Slightly volatile
Capex To Revenue0.08290.05510.0764
Slightly volatile
Cash Per Share0.910.962.6897
Slightly volatile
Days Payables Outstanding86.3757.1762.2021
Slightly volatile
Income Quality0.721.190.6316
Pretty Stable
Intangibles To Total Assets0.470.260.3488
Slightly volatile
Current Ratio4.266.564.2074
Pretty Stable
Receivables Turnover4.154.675.4883
Pretty Stable
Capex Per Share0.02590.02720.1975
Slightly volatile
Revenue Per Share0.540.572.2512
Slightly volatile
Interest Debt Per Share0.110.123.2053
Slightly volatile
Debt To Assets0.05890.0620.3738
Slightly volatile
Operating Cycle279271227
Slightly volatile
Days Of Payables Outstanding86.3757.1762.2021
Slightly volatile
Ebt Per Ebit0.880.711.0692
Pretty Stable
Quick Ratio3.755.853.7277
Pretty Stable
Net Income Per E B T1.081.150.993
Slightly volatile
Cash Ratio1.952.911.8283
Pretty Stable
Cash Conversion Cycle193213165
Pretty Stable
Days Of Inventory Outstanding196190158
Slightly volatile
Days Of Sales Outstanding82.9880.8769.2341
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.431.221.3629
Pretty Stable
Fixed Asset Turnover2.672.816.1225
Slightly volatile
Debt Ratio0.05890.0620.3738
Slightly volatile
Price Sales Ratio4.324.074.0572
Slightly volatile
Asset Turnover0.480.330.3803
Very volatile
Gross Profit Margin0.620.560.5719
Slightly volatile

Standard Biotools Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap478.1 M393.1 M462.3 M
Slightly volatile
Enterprise Value274.1 M376.6 M363.4 M
Slightly volatile

Standard Fundamental Market Drivers

Standard Upcoming Events

13th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Standard Biotools Financial Statements

Standard Biotools stakeholders use historical fundamental indicators, such as Standard Biotools' revenue or net income, to determine how well the company is positioned to perform in the future. Although Standard Biotools investors may analyze each financial statement separately, they are all interrelated. For example, changes in Standard Biotools' assets and liabilities are reflected in the revenues and expenses on Standard Biotools' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Standard Biotools. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue21.4 M22.4 M
Total Revenue200.6 M210.6 M
Cost Of Revenue103.7 M108.9 M
Stock Based Compensation To Revenue 0.16  0.09 
Research And Ddevelopement To Revenue 0.41  0.62 
Capex To Revenue 0.06  0.08 
Revenue Per Share 0.57  0.54 
Ebit Per Revenue(0.90)(0.95)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Standard Biotools offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Standard Biotools' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Standard Biotools Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Standard Biotools Stock:
Check out the analysis of Standard Biotools Correlation against competitors.
For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. If investors know Standard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Standard Biotools listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.39)
Revenue Per Share
0.448
Quarterly Revenue Growth
(0.14)
Return On Assets
(0.15)
Return On Equity
(0.33)
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Standard Biotools' value and its price as these two are different measures arrived at by different means. Investors typically determine if Standard Biotools is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Standard Biotools' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.